Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Solid Biosciences is a clinical-stage gene therapy company focused on developing treatments for Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting approximately 1 in 3,500-5,000 male births. The company's lead candidate SGT-003 is an AAV-based gene therapy designed to deliver micro-dystrophin to muscle tissue, currently in Phase I/II clinical trials following previous setbacks with earlier candidates. With zero revenue and negative operating cash flow of $100M annually, the stock trades on clinical trial milestones, regulatory developments, and cash runway visibility.
Solid operates a classic biotech development model: raise capital through equity offerings and debt, invest in clinical trials and manufacturing, seek FDA approval, then commercialize through direct sales or partnerships. Gene therapies for rare diseases command premium pricing ($1-3M per patient one-time treatment) due to small patient populations (estimated 12,000-15,000 DMD patients in US) and transformative clinical benefits. Success depends on demonstrating durable micro-dystrophin expression, functional improvement in muscle function, and acceptable safety profile. The company has no current pricing power as it generates no revenue; future pricing will depend on comparative efficacy versus Sarepta's approved therapies and payer willingness to reimburse.
SGT-003 clinical trial data releases - micro-dystrophin expression levels, functional endpoints (6-minute walk test, North Star Ambulatory Assessment scores)
FDA regulatory interactions - IND clearances, clinical hold resolutions, breakthrough therapy designation decisions
Cash position updates and equity financing announcements - runway visibility critical given $100M annual burn
Competitive developments from Sarepta Therapeutics, Pfizer, and other DMD gene therapy programs
Manufacturing and CMC progress - successful tech transfer to commercial-scale facilities, process validation milestones
Gene therapy manufacturing complexity and scalability - AAV vector production requires specialized facilities with limited global capacity, creating supply chain bottlenecks and high COGS risk
Regulatory uncertainty for novel gene therapies - FDA requiring longer-term durability data (5-10 years) before approval, potential for clinical holds due to immune responses or off-target effects
Reimbursement challenges for ultra-high-cost therapies - payers increasingly resistant to $2-3M one-time treatments without outcomes-based contracts or installment payment structures
Sarepta Therapeutics' established DMD franchise with approved exon-skipping therapies and competing gene therapy programs creates high bar for differentiation
Pfizer's fordadistrogene movaparvovec gene therapy program in late-stage development with potentially superior micro-dystrophin construct and manufacturing scale
Risk of becoming 3rd or 4th entrant in DMD gene therapy market with limited remaining patient population and physician preference already established
Equity dilution risk from future capital raises - pre-revenue biotechs typically require 3-5 financing rounds before commercialization, diluting existing shareholders 70-90%
Cash runway pressure if clinical trials encounter delays - current $100M annual burn provides approximately 2-3 year runway based on current ratio, but trial extensions could accelerate financing needs
Negative ROE of -73.6% and ROA of -61.0% reflect accumulated losses and capital consumption inherent to clinical-stage model
low - Pre-revenue biotechs are largely insulated from GDP fluctuations as they generate no sales. However, severe recessions can impact: (1) ability to raise capital as risk appetite declines, (2) clinical trial enrollment if patients defer elective procedures, (3) partnership valuations if pharma acquirers reduce M&A activity. DMD is a severe progressive disease where treatment decisions are not discretionary, providing demand stability post-approval.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (estimated 2029+ for SGT-003 revenue). Clinical-stage biotechs with no earnings trade primarily on NPV of pipeline assets, making them sensitive to risk-free rate changes. Higher rates also increase financing costs for future capital raises and make cash-burning growth stocks less attractive relative to fixed income. However, Solid's minimal debt (0.10 D/E) limits direct interest expense impact. The 23% stock rally over 3 months suggests rate stabilization expectations may be supporting valuation.
Minimal direct credit exposure given negligible debt and strong current ratio of 6.74x. Primary credit risk is access to capital markets for future equity raises - tightening credit conditions reduce institutional appetite for speculative biotech offerings. High-yield spreads widening above 500bps historically correlates with biotech IPO/follow-on windows closing. The company's ability to maintain 2-3 year cash runway depends on continued access to growth equity capital.
growth/speculative - Attracts biotech-focused hedge funds, venture capital crossover funds, and retail investors seeking asymmetric risk/reward from binary clinical outcomes. Not suitable for value or income investors given zero revenue, negative cash flow, and no dividend. The 3.8% one-year return with high volatility (23% gain in 3 months, -8.8% over 6 months) reflects event-driven trading around clinical milestones. Typical holders include specialized healthcare funds willing to underwrite 5-7 year development timelines and accept 70-90% downside risk for potential 300-500% upside if SGT-003 succeeds.
high - Clinical-stage biotechs exhibit 60-100% annualized volatility driven by binary trial outcomes, regulatory decisions, and financing events. Single data releases can move stock 30-50% in either direction. The stock's recent performance (23% 3-month gain despite -8.8% 6-month decline) demonstrates characteristic whipsaw behavior. Small market cap of $400M amplifies volatility as institutional flows represent larger percentage of float. Expect continued high beta (likely 1.5-2.5x) relative to broader market until revenue generation reduces business risk.
